Skip to main content
Premium Trial:

Request an Annual Quote

Arrowhead to Raise $104M in Stock Offering

Premium

Arrowhead Research this week announced that it will sell 5.5 million shares of its common stock at $18.95 apiece for gross proceeds of $104 million.

The company has also granted the underwriters of the offering an option to buy an additional 825,000 shares, which would add another $15.6 million.

The company said the offering is expected to close early next week. The funds raised will be used for general corporate purposes, including research and development.

Earlier this month, the company said that it had filed with US regulators to sell up to $200 million in common stock, preferred stock, and/or warrants. At the time, Arrowhead President and CEO Christopher Anzalone said that the ability to sell the securities would give the company the ability to fully develop its lead hepatitis B treatment, ARC-520.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.